Comparative analysis of cefoperazone-sulbactam and piperacillin-tazobactam in empirical treatment of acute biliary tract infections: a multicenter, retrospective, real-world study
Abstract Patients diagnosed with acute cholecystitis or cholangitis admitted to three tertiary Grade A hospitals between January 2022 and March 2026 were enrolled. All subjects were divided into the cefoperazone-sulbactam group and piperacillin-tazobactam group according to the initial empirical ant...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Portfolio
2026-07-01
|
| Serija: | Scientific Reports |
| Teme: | |
| Online pristup: | https://doi.org/10.1038/s41598-026-63210-x |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|